Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

@article{Brown2013LongtermOO,
  title={Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.},
  author={David M. Brown and Quan D. Nguyen and Dennis M. Marcus and David S Boyer and Sunil I. Patel and Leonard Feiner and Patricio G. Schlottmann and Amy Chen Rundle and Jiameng Zhang and Roman G. Rubio and Anthony P. Adamis and Jason S Ehrlich and Jill J. Hopkins},
  journal={Ophthalmology},
  year={2013},
  volume={120 10},
  pages={2013-22}
}
PURPOSE To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of ranibizumab in diabetic macular edema (DME). DESIGN Phase III, randomized, multicenter, double-masked, 3-year trials, sham injection-controlled for 2 years. PARTICIPANTS Adults with DME (n=759), baseline best-corrected visual acuity (BCVA) 20/40 to 20/320 Snellen equivalent, and central foveal thickness (CFT) ≥ 275 μm on optical coherence tomography. METHODS Patients were randomized equally (1 eye… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS